Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:approves |
gptkb:2013
gptkb:FDA |
| gptkbp:atccode |
L04 AA31
|
| gptkbp:brand |
gptkb:Tecfidera
|
| gptkbp:casnumber |
624-49-7
|
| gptkbp:chemical_formula |
C6 H8 O4
|
| gptkbp:composed_by |
from fumaric acid
|
| gptkbp:dissolved |
soluble in water
|
| gptkbp:financial_stability |
stable under normal conditions
|
| https://www.w3.org/2000/01/rdf-schema#label |
dimethyl fumarate
|
| gptkbp:mass |
144.13 g/mol
|
| gptkbp:mechanism_of_action |
activates Nrf2 pathway
|
| gptkbp:previous_name |
dimethyl (E)-butenedioate
|
| gptkbp:related_products |
fumaric acid
monomethyl fumarate |
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
gastrointestinal disturbances
flushing |
| gptkbp:storage |
store at room temperature
|
| gptkbp:structure |
gptkb:oil_and_gas_industry
|
| gptkbp:used_for |
treatment of multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Tecfidera
|
| gptkbp:bfsLayer |
6
|